ORETICYL FORTE Drug Patent Profile
✉ Email this page to a colleague
When do Oreticyl Forte patents expire, and when can generic versions of Oreticyl Forte launch?
Oreticyl Forte is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in ORETICYL FORTE is deserpidine; hydrochlorothiazide. There are four drug master file entries for this compound. Additional details are available on the deserpidine; hydrochlorothiazide profile page.
Summary for ORETICYL FORTE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ORETICYL FORTE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ORETICYL FORTE
US Patents and Regulatory Information for ORETICYL FORTE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | ORETICYL FORTE | deserpidine; hydrochlorothiazide | TABLET;ORAL | 012148-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |